L
Logos Global Management, L.P.
+ HoldingYARW
+26.29%
3M Return
$30.210
+1.423 (+4.71%)收盤時
Loading chart…
- High
- 31.900
- Open
- 29.340
- VWAP
- 30.38
- Vol
- 26.58K
- Mkt Cap
- —
- Low
- 29.040
- Amount
- 807.50K
- EV/EBITDA, TTM
- 0.00
Yarrow Bioscience, Inc. is a clinical-stage biotechnology company focused on developing transformative therapies for autoimmune thyroid diseases. The Company is developing YB-101, an anti-thyroid stimulating hormone receptor (TSHR) monoclonal antibody designed to directly and rapidly disrupt the central mechanism of both Graves' Disease (GD) and Thyroid Eye Disease (TED), offering a single targeted treatment to address both diseases. By blocking TSHR, the common target of autoantibodies in both the thyroid and the eye, YB-101 has the potential to rapidly arrest the disease process and provide improved efficacy and safety versus the standard of care and other mechanisms in development. YB-101 is designed for convenient subcutaneous administration, with the potential for infrequent dosing and future autoinjector presentations. The Company has initiated dosing in a Phase 2a/2b trial evaluating YB-101 in patients with GD, with or without concurrent TED.
AI analysis of YARW (YARW)
buyYarrow Bioscience Inc is a good buy right now due to its recent FDA Fast Track designation for YB-101, which positions it favorably in the market, and an analyst price target of $58, indicating a potential upside of approximately 92% from the current price of $30.21. The company has a strong gross margin of 100%, reflecting its potential for profitability once it scales operations, despite current net income losses.
估值指標
The current forward P/E ratio for YARW (YARW) is 0.00, compared to its 5-year average forward P/E of .
Whales holding YARW
事件時間軸
資訊
YARW FAQ — answered by Alphio AI
Yarrow Bioscience Inc is a good buy right now due to its recent FDA Fast Track designation for YB-101, which positions it favorably in the market, and an analyst price target of $58, indicating a potential upside of approximately 92% from the current price of $30.21. The company has a strong gross margin of 100%, reflecting its potential for profitability once it scales operations, despite current net income losses.
本頁僅供研究參考，不構成投資建議。模型可能出錯。過往表現不代表未來結果。